Evelo Forges Ahead In Psoriasis As Atopic Dermatitis Pathway Narrows

Company Reveals Layoffs To Stay On Course

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The company said the first three cohorts of its Phase II atopic dermatitis study failed, while another trial with a faster-release formulation of EDP1815 continues, along with a Phase III study in psoriasis.

PSORIASIS Text, On Background of Medicaments Composition, Stethoscope, mix therapy drugs doctor flu antibiotic pharmacy medicine medical

Evelo Biosciences, Inc. cited an unusually high placebo response rate in the first three cohorts of its Phase II clinical trial of EDP1815 in atopic dermatitis on 1 February as it announced the study failed to meet its primary endpoint. This may significantly narrow the potential path forward for the drug, but the company still sees a route to registration for it and another drug, EDP2939, in psoriasis. Given the atopic dermatitis setback, however, Evelo plans to restructure and lay off some of its workforce.

The Phase II atopic dermatitis study that showed an unusually high placebo response rate had a primary endpoint of patients...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D